Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sal CURB is a veterinary feed antimicrobial product marketed by Kemin for livestock and poultry feed biosecurity. The core marketed liquid product is described as a blend of aqueous formaldehyde 37 percent solution and propionic acid that is applied to complete feeds and feed ingredients to maintain **Salmonella**-negative status for up to 21 days and to control mold. It is used as a feed treatment rather than a systemic therapeutic drug, and its antimicrobial effect is based on direct chemical inactivation of pathogens in feed; formaldehyde can crosslink and denature microbial proteins and nucleic acids, while propionic acid contributes preservative and antimicrobial activity. The Sal CURB franchise also includes region- or use-specific variants and dry surface-disinfection products, so the exact composition depends on the specific Sal CURB product variant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sal CURB.